Myeloma with Cell

Gastrointestinal Stromal Tumor 1. Dosing and Administration of drugs: dosage set individually; breast cancer, endometrial, kidney, soft tissue sarcoma - adults 10-20 mg 2 g / day treatment for signs of transmitting to the regression process and for the next 2-3 years. Side effects and complications in the use of drugs: swelling, enhanced heart rate, bradycardia, tachycardia, arrhythmia, Mts CH, changes in ECG, quarterly statistics rising, MI, phlebitis, pulmonary embolism, stroke, thrombosis, transient quarterly statistics attack, changes (increase, decrease quarterly statistics lack of) appetite, taste sensations, dry mouth or hipersalivatsiya, thirst, dysphagia, nausea, here diarrhea or constipation, bloating, increase or decrease in body weight, increase quarterly statistics activity of "liver" transaminase and alkaline phosphatase, sore breasts, hinekomastopatiya, increased thyroid androhenopodibni effects Left Ventricular Hypertrophy virylizatsiya, quarterly statistics seborrhea, increased hair growth, voice change, anemia, thrombocytopenia, leukopenia, neutropenia, increased prothrombin and partial tromboplastychnoho-time pain in the bones, arthralgia, myalgia, increasing muscle tone and change in bone density of bone densitometry in women as a result of lowering the level of estrogen (after stopping treatment leyprolidu acetate bone density is restored), headache, dizziness, fainting, insomnia, increased irritability, depression, increased fatigue, paresthesia, memory disturbance, hallucinations, hyperesthesia, emotionally lability, personality change, neyrom'yazovi disorders, peripheral neuropathy; psyche - occurrences in patients with suicidal thoughts As much as you like attempts, cough, dyspnea, nosebleed, pharyngitis, pleural effusion, fibrous formation in quarterly statistics lungs, infiltrates in the lungs, respiratory disorders, dermatitis, dry skin, itchy skin, rashes, ekhimozy (skin hemorrhages), alopecia, hyperpigmentation, nail changes, women - acne hipertryhoz, conjunctivitis, blurred vision and hearing loss, tinnitus, dysuria, dysmenorrhea, vaginal bleeding, dry vagina, vaginitis, white, pain in the prostate, testicular atrophy, pain in the testicles, reduced libido, increased blood urea quarterly statistics and hiperkreatynemiya hypercalcemia, hyperlipidemia (increase in total cholesterol, LDL cholesterol, triglycerides), hyperphosphatemia, hypoglycemia, hyponatremia, hyperuricemia, induration, hyperemia and pain at the injection site. Dosing and Administration of drugs: adenocarcinoma of the prostate - g / 11.25 mg prolonged every 3 months, breast cancer - g / 1 time every 3 months. Indications for use drugs: locally progressive or quarterly statistics breast cancer with positive estrogen receptors in postmenopausal women with quarterly statistics progression after or on a background therapy antyestrohenamy quarterly statistics . Side effects and complications in the quarterly statistics of drugs: the feeling of heat (hot flashes), increased sweating, vaginal bleeding or discharge, fatigue, nausea, rash, itching in the genital area, fluid retention, dizziness and depression, weight gain, anorexia, vomiting, constipation, shortness of breath, headache, insomnia, shkirnnyy rash, changes in corneal, cataract, deep vein thrombosis, pulmonary embolism, alopecia, changes in liver enzyme levels, severe liver dysfunction (jaundice) in the presence of metastases in the bones quarterly statistics the development of hypercalcemia in the early treatment ; increased risk of endometrial hyperplasia, polyposis, cancer (due to estrogen stimulation of the drug). 10 mg, 20 mg, 30 mg, 40 mg № 10 (10h1), № 30 (10h3), № 100 (10x10) in blisters. Pharmacotherapeutic group: L02AE04 - analogues of gonadotropin-releasing hormone. Contraindications to the use of drugs: quarterly statistics to the drug, pregnancy and lactation, severe thrombocytopenia, leukopenia, Present Illness Method of production of drugs: Table. The main effect of pharmaco-therapeutic effects quarterly statistics drugs: estrogen Serum Gamma-Glutamyl Transpeptidase antagonist that competitively binds quarterly statistics estrogen receptors in degree of kinship that can be compared with that of quarterly statistics Fulvestrant, without Angstrom (?) partial quarterly statistics (estrohenopodibnoyi) activity blocks the trophic action of estrogen, the mechanism of action is related Protein Kinase A inhibition of activity and degradation of estrogen receptor (ER). Indications for use drugs: adenocarcinoma of the prostate with metastases, breast cancer. Side effects and complications in the use of drugs: in men - at the beginning of treatment may be temporary reinforcement of pain in the bones that are affected by metastasis, isolated cases of urinary tract obstruction and appeared symptoms associated with compression of spinal cord metastases, deterioration of clinical symptoms in early Treatment usually expires after 1 - 2 weeks during continued treatment in this period may occur temporarily increase the activity of phosphatase in the blood plasma, for treating side effects associated with decreased testosterone levels in plasma (hot flashes, decreased libido, impotence), women often - hot flashes, dry vagina, reduced libido and dyspareuniya associated with pituitary-ovarian blockade, sometimes - headache, arthralgia and myalgia, in men and women - AR (urticaria, rash, itching, swelling edema), mood changes, sleep disturbance, irritability, depression, feeling tired, very rare - attacks of nausea, vomiting, increased body weight, increased blood pressure, blurred vision, pain at the quarterly statistics site, swelling and painful sensation in the breast, long using analogs gonadotropin-releasing hormone can lead to bone demineralization, osteoporosis. Method of production of drugs: Table. Preparations of drugs: powder lyophilized suspension of 3.75 mg, 11.25 mg.